In addition to triggering a myeloid inflammatory response, KRAS-mutant pleural tumours and MPEs showed enhanced angiogenic and vasoactive potential in several in vivo assay systems compared with KRAS-wild-type tumours (Supplementary Fig. 2b–d). Here, KRAS is linked to pleural neoplasm.